DOCSLIB.ORG

Industry Leading Organizations Who Attended DIA 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Industry Leading Organizations Who Attended DIA 2017 Industry Leading Organizations Who Attended DIA 2017 3D Communications ADAMAS Consulting LLC Allscripts 3I ADAMAS Consulting Ltd Allscripts Analytics 3vue, LLC Adams Clinical Almac Group 4C Pharma Solutions LLC Adaptimmune Alnylam 4G Clinical Adaptive Clinical Systems Alnylam Pharmaceuticals, Inc. 5AM Solutions Adare Pharmaceuticals Altasciences Clinical Research A2 Healthcare Corporation Addison Whitney Altavoz, Inc. Abbott Laboratories Adobe Alzheimer's Association Abbott Medical Optics Adriaus Consulting AMAG Pharmaceuticals Abbott Point Of Care Advanced Clinical AMC Health Abbvie Advanced Clinical Research American Solutions for Business AbbVie Deutschland GmbH & Co. Aeglea Biotherapeutics America's Health Insurance Plans KG Aerie Pharmaceuticals, Inc. (AHIP) AbbVie GK Aerotek Amgen Abbvie Inc. Aetna, Inc. Amgen GmbH Abbvie Taiwan Ltd. AG Mednet, Inc. Amgen Inc AbbVie, Inc. AGA Clinical Trials Amgen Inc. Abingworth Agatha Inc. Amgen, Inc. ABS Capital Parnters Agência Nacional De Vigilância Amicus Therapeutics ACADIA Pharmaceuticals Inc. Sanitária (ANVISA) AMPLEXOR Life Sciences Accel Clinical Services Agency For Healthcare Research AMPLEXOR Life Sciences, LLC and Quality (AHRQ) Accelerated Cure Project Amulet Capital Partners AgilePV Acceleron Pharma Anaheim Clinical Trials Agios Accenture Ancillare, LP Agios Pharmaceuticals Accenture Accelerated R&D Andwin Scientific Services AGTC Anju Software Accenture LLP AiCure Ann and Robert H. Luie Childrens' Access BIO Aimmune Therapeutics, Inc. Hospital Kids Advisory Board Accurate Clinical Management, Ajou University School of Medicine Antidote LLC Akebia Therapeutics, Inc. APCER Life Sciences Accurate Clinical Research Akros Pharma Inc. Apex Life Sciences Acerta Pharma Alcon Laboratories Apex Medical Research Aces Health Alder Biopharmaceuticals APHP University Hospital Achaogen, Inc. Alexion Appian Ache Lab Pharma Algorics Appian Corporation Achillion Pharmaceuticals, Inc AliveCor, Inc. Appili Therapeutics Inc. Achillion Pharmaceuticals, Inc. ALK-Abello Danmark A/S Applied Clinical ACI Clinical Alkahest, Inc Trials/Pharmaceutical Executive ACM Global Laboratories Alkermes Aquila Solutions, LLC ACRP Allergan ARCH Actelion Allergan Japan K.K. Archigen Biotech Limited ActiGraph Alliance for Multispeciality ARCO Design/Build - Build to Suit Activa CRO Research Ardea Biosciences (AstraZeneca Acuma Group Alliance for Safe Biologic Medicines Group) Acurian Alliance Research Centers Ariad Pharmaceuticals Inc. Industry Leading Organizations Who Attended DIA 2017 ArisGlobal Audubon PM Associates BeiGene ARISGlobal LLC & Representative August Research Beijing Clinical Service Center Director, AGKK, Tokyo, Japan Aurinia Pharmaceuticals Inc. Bellicum Pharmaceuticals, Inc ARITHMOS Aurobindo Benchmark Research ArQule, Inc. Aurora Research Institute, Aurora Berkery Noyes & Co., LLC Array Biopharma Baycare Medical Center Berry Consultants Array BioPharma Inc. Author-it Software Corporation BGI Arsenal Capital Partners Autotelic Inc Bill & Melinda Gates Foundation Artcraft Health Avanir Bio Pharma Services, Inc. Arthritis Foundation Avanir Pharmaceuticals Biocentury ARUP Laboratories Avego Healthcare Capital BioClin Therapeutics, Inc. Asahi Kasei Pharma America Avexis, Inc. Bioclinica Asan Medical Center Axelerist Financial BioCryst Pharmaceuticals, Inc. Ascendis Pharma Axiom Real-Time Metrics BioDigital ASD Healthcare AxxiTRIALS (Litera) Bioelectron Technology Ashfield Healthcare B. Braun Medical, Inc Corporation Aspen Consulting, LLC BAFallen Consulting LLC BioEq, LLC Aspire IRB Baird BioFortis assisTek Banook Group - Cardiabase Biofortis Merieux NutriSciences Associated Medical Clinical BARC Global Central Lab Biofortis Research Science Services Barnett International Bioforum Association for Accessible Barrington James Biogen Medicines (AAM) Barton Associates Biogen/Mcphs Association of Clinical Research Professionals (ACRP) BASi Biogen; MCPHS University Association of the British Baxalta, Now Part of Shire Biomapas Pharmaceutical Industry (ABPI) Baxter Biomarin Pharmaceutical Inc. Assurex Health Baxter Healtcare Biomarin Pharmaceuticals Astellas Baxter Healthcare Biomedical Systems Astellas Pharma Bay Area Biotech' BiomedwoRx Astellas Pharma Global Bayer Bio-Optronics, Inc. - Clinical Development, Inc. Bayer AG Conductor CTMS Astellas Pharma Inc. Bayer Business Service Gmbh BioPharm Insight Astellas Pharma Korea, Inc. Bayer Business Services BioPharma Dive Astellas Pharma US, Inc. Bayer Healthcare Company Biophia Asterias Limited BioPoint AstraZeneca Bayer HealthCare Pharmaceuticals BioPoint Inc Astrazeneca HK Bayer S.A. BioSelect Inc. Astrazeneca Hong Kong Limited Baylor College of Medicine Bioserv SMO Atara Biotherapeutics BBK Worldwide Bioskin Gmbh Athena Health BC Cancer Agency BioTelemetry Research athenahealth BDSI BioTelemetry, Inc. Atlant Clinical Beacon Hill Pharma Biotrack Aps Atlanta Center For Medical Beaufort Bioverativ Research Beaufort LLC Biovista Inc. Atlantic Exhibits Beazley Group BizInt Solutions, Inc. Industry Leading Organizations Who Attended DIA 2017 Blankstein Consulting Group Camargo Pharmaceutical Services, CG Life Blinded Diagnostics LLC CGI BloodCenter of Wisconsin Cambridge Cognition Chang Gung Medical Foundation- Blue Reg Group Cambridge Healthtech Institute Linkou Branch Blue Ridge Capital Campbell University Channel Methods Bluebird Bio Cancer Genetics, Inc. Channel Methods Partners BlueCloud By HealthCarePoint CANCER101 Channel Methods Partners, LLC Boehringer Ingelheim Canfield Scientific, Inc. Chaucer Boehringer Ingelheim Cardiabase By Banook Group Chesapeake IRB Pharmaceuticals Inc. Cardinal Health Chiba University Boehringer Ingelheim Cardinal Health Regulatory Chiba University Hospital Pharmaceuticals, Inc. Sciences Chicago Research Center Bombay College Of Pharmacy CareFusion Research Services Chiesi USA Booz Allen Hamilton Catalent Pharma Solutions Chiltern Booz Allen Hamilton Inc Catalyst Clinical Research Chimerix, Inc Boston Consulting Group Catalyst Healthcare Consulting, Inc China Food and Drug Boston Pharmaceuticals Catalyst Regulatory Services, LLC Administration (CFDA) Boston Scientific Corporation CCC China Food and Drug Bracco Diagnostics Inc. CCRA Adminsitration (CFDA) Bracken Marketing CCS Associates China Medical University Hospital - Clinical Trials Center BrackenData CDC Christie Clinic Bracket CDISC Chubb Limited Brahman Capital Corp. CDM Consulting Chugai Pharma Taiwan Ltd. Brand Institute Ce3 Chugai Pharma USA BRANY Celerion Chugai Pharma USA, Inc. Brave Warrior Advisors Celgene Corp Chugai Pharmaceutical Co., Ltd. Brian Beger, LLC Celgene Corporation Cincinnati Children's Hospital Brigham and Women's Hospital Celgene Global Safety and Risk Management Cincinnati Children's Hospital Bring Life Sciences Consulting, Inc Medical Center Celgene Turkey Brio Resource Group Cincinnati Children's Research Bristol Myers Squibb Cellics Therapeutics, Inc. Foundation Bristol Myers-Squibb Celltrion CinRx Pharma Bristol-Myers Squibb Celltrion, Inc CIOX Health Bristol-Myers Squibb Company Celltrion, Inc. Cipher Pharmaceuticals Inc. Bristows LLP Cenduit Circassia Pharmaceuticals, Inc. Bryan Katz Cenduit LLC CISCRP BSI Group America Inc. Center For Drug Evaluation CitiusTech Inc. Busanpaik University Hospital CTC Center For the Study of Drug City of Hope Development, Tufts University Business Review Webinars School of Medicine CJD Consulting Inc. ByteGrid CenterWatch Clariness C&R Research Centre for Human Drug Research Clarivate Analytics C3i Healthcare Connections Centre For Innovation In Clark Life Science Consulting LLC CAC Croit Corporation Regulatory Science (CIRS) Clearside Biomedical, Inc Cadient Centre for Osteopathy Clearside Biomedical, Inc. Certara G.K. Cleave Biosciences Industry Leading Organizations Who Attended DIA 2017 ClientLink CluePoints Cortellis Clinactis Cmed Corvalus ClinActis Pte Ltd Cmed Clinical Services Corvus Pharma Clincapture CMIC Asia-Pacific, Pte. Ltd. Costa Rican Investment Promotion ClinDatrix Inc. CMIC Co., Ltd. Agency (CINDE) ClinDatrix, Inc. CMIC HOLDINGS Co., Ltd. Court Square Group, Inc. ClinEdge CMIC Korea Co., Ltd. Court Square Group/RegDocs 365 Clinerion CMIC, Inc. Court Square Group/RegDocs365 Clinerion Ltd CMM Global Inc Covance Clinical Biosafety Services, LLC CMM Global Inc. Covance Inc. Clinical Conductor CTMS CNS Healthcare Covance Market Access Services Clinical Data Intechange Standards Coalition For Healthcare Covilance LLC Consortium (CDISC) Communication Covington & Burling LLP Clinical Informatics News Cognizant CRA Assessments Clinical Ink Cognizant Technology Solutions CREDIT SUISSE Clinical Leader Cognizant Technology Solutions CRF Health Clinical Quality Assured, LLC Corporation Crimson Interactive - Ulatus Clinical Reference Lab Cogstate Crimson Interactive INC Clinical Reference Laboratory Coherus BioSciences Crimson Interactive Pvt. Ltd. Clinical Research Altasciences Colgate-Palmolive Company Critical Path Institute Clinical Research Associates Inc Columbia University CRN - Clinical Research Network Clinical Research Atlanta Commonwealth Informatics CRO Analytics Clinical Research Consortium, An Complete Healthvizion CROMSOURCE AMR Company CompleWare Corporation Cronos CCS, Inc. Clinical Research Consultant, Compliance Meds Technologies CROS NT Adjunct Faculty Comprehend CROS NT / Wings for Life Spinal Clinical Research IO Comprehend Systems Cord Research Foundation Clinical Research Malaysia Comprehend Systems, Inc. CROS NT srl Clinical Research Management Concordia International
Load more

Recommended publications
  • 2017 Sustainability Report
    2017 SUSTAINABILITY REPORT CREATING A BETTER WORLD CONTENTS WHO WE ARE CREATING A BETTER WORLD 4 About this Report 10 Business Overview 24 Our Goals 6 Letter from our CEO 13 Our Products 29 Our Planet 8 About Medidata OUR APPROACH GRI INDEX 14 Stalkholders 30-32 GRI Index 16 Materials References: PEOPLE FIRST Priority Issue: An issue deemed material to the company through our sustainability issue prioritization process. 18 Ethics Global Reporting Initiative (GRI): The GRI Sustainability Reporting Standards are the first and 20 Our People most widely adopted global standards for sustainability reporting. 22 Diversity Matters UN Global Compact: The UNGC is a voluntary initiative based on CEO commitments to implement universal sustainability principles and to understand partnerships in support of UN Goals. Sustainable Development Goals: The SDGs are a universal call to action to end poverty, protect the planet, and ensure that all people enjoy peace and prosperity. 2 2017 MEDIDATA SUSTAINABILITY REPORT 2017 MEDIDATA SUSTAINABILITY REPORT 3 CREATING A CREATING A WHO WE ARE OUR APPROACH PEOPLE FIRST BETTER WORLD GRI INDEX WHO WE ARE OUR APPROACH PEOPLE FIRST BETTER WORLD GRI INDEX About this Report Letter from our CEO About Medidata Business Overview Our Products About this Report Letter from our CEO About Medidata Business Overview Our Products ABOUT THIS REPORT As we reflect on the last 18 years, the spirit of No information contained on our website is innovation—one that has truly paved the way intended to be included as part of, or incorporated for better solutions, higher quality treatments, by reference into, this Annual Report on Form and quicker go-to-market times—remains our 10-k.
    [Show full text]
  • Symbols Alexian Brothers Health System Index to Nov P
    Volume 19, Index December 2014 Symbols Alexian Brothers Health System Index to Nov p. 2 Health Care M&A News 1-800-CONTACTS Feb p. 18 A&L Goodbody Apr p. 16, July p. 16 All Care Home Health, LLC Feb p. 17 Each company and orga- A Allergan Inc. Feb p. 10, May p. 1, nization discussed in Health May p. 19, Jun p. 15, July p. 3, Care M&A News, from Janu- Abbott Labs July p. 3, Aug p. 17, July p. 10, Sept p. 16, Oct p. 3, ary through December 2014, Dec p. 4 Nov p. 1, Dec p. 4, Dec p. 16, is listed alphabetically here. AbbVie Inc. July p. 3, July p. 16, Dec p. 19 References are typically to Aug p. 9, Oct p. 2, Oct p. 16, Allscripts Feb p. 2, Apr p. 10 the first occurrence of the Nov p. 19, Dec p. 2 AllSpire Health Partners Nov p. 2 company’s or organiza- ABL, Inc. Aug p. 18 All Staffing Services Jan p. 17 tion’s name in the pertinent Acadia Healthcare Company Feb p. 16, Almost Family, Inc. Apr p. 16 issue; further discussion July p. 17, Oct p. 17, Nov p. 17 ALN Medical Management, LLC may follow later in the text Accelera Innovations, Inc. Jan p. 17 Accelrys, Inc. Jan p. 15 Feb p. 8 but is not indicated here. AccessClosure, Inc. May p. 15 Alta Partners Jun p. 16 Achillion Pharmaceuticals July p. 17 Altos Solutions, Inc. Jun p. 15 References are sorted by Actavis (Foshan) Pharmaceuticals Co.
    [Show full text]
  • Preclinical Development & IND Filing: Nuts, Bolts, Best Practices
    “Preclinical Development & IND Filing: Nuts, Bolts, Best Practices and Regulatory Aspects.” Speakers: Amit Kalgutkar (Pfizer), Chandra Prakash (Agios), Sanjeev Thohan (Novartis), Li- Chun Wang (Takeda), Wei Yin (Biogen) Organizers: Sanjeev Thohan and Chandra Prakash Date: 6/29/2017 Time: 8:30 am – 5.00 pm Location: Boston/Cambridge Area: Marriott Kendall Square, 50 Broadway, Cambridge MA 02142 Fees: $175 - Regular (before June 1st, 2017), $225 - Regular (after June 1st, 2017); $125 - Unemployed & Academic; $2000 - Major Sponsorship; $475 - Vendor Show Registration: www.PBSS.org Workshop Description: An investigational new drug application (IND) is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations and processes of assembling an IND is a key to not only successful filing, but also a promising clinical development path forward. Often there are cases where too many of our “nice-to-have” studies crowd the package at the expense of critical study needs/issues. This can lead to significant delays in clinical developments with back-and-forth of Q&A sessions both internally and with regulatory agencies. As we have seen, the regulatory landscape is changing as rapidly as the industry innovates into new therapeutic modalities. Therefore, it is critical to keep up to date on regulatory requirements and the industry’s best practices in different aspects of the IND: non- clinical safety, PK, CMC, and clinical plans. In this workshop, our speakers who bring years of experience with multiple successful IND filings, will discuss systematically the preclinical studies required for small molecule IND’s as well as the nuts and bolts of putting together a high–quality IND package.
    [Show full text]
  • Honoring Catalysts in Action Over the Winter and Spring Through Our Website, Facebook and Twitter
    8 CONNEC TCFS We have been honored to share the stories of 25 Catalysts Honoring Catalysts in Action over the winter and spring through our website, Facebook and Twitter. We hope you’ll take time to read about their remarkable lives and the courage and persistence they Throughout this issue of SolveCFS we pay tribute to the collective action demonstrate every day. As unique as each one is, they are united in their hope that research led by the CFIDS that has led up to the launch of the Association’s latest research initiative: Association of America will lead to better treatment and the research institute without walls (RIWW). Two individuals warrant spe - healthier futures. cial attention for their immensely important contributions. First, James York , the first person consented and enrolled to participate in the SolveCFS BioBank. James was working as an underwater camera man and marine coordinator in the film industry when pneumonia turned into CFS in 2004. He has turned to writing when cognitive impairment can be kept at bay, as a form of expression and, occasionally, compensation. James enrolled in the BioBank as soon as it was announced. He returned his signed consent James York, adrift and at work on the form promptly; completed the extensive medical award-winning film “Ocean Men: Extreme history questionnaire thoroughly and expeditiously Dive” with an IMAX Mark II camera and even recruited his own matched control to partici - housing in Stargate Cave on Andros Island pate. He gave blood samples and tissue swabs. He did in the Bahamas. The picture explored the so as part of an odyssey to learn about CFS and cope beauty and science of breath-hold diving with it.
    [Show full text]
  • Healthcare & Life Sciences Group
    HEALTHCARE & LIFE SCIENCES GROUP 2 1 Healthcare and life sciences clients have long turned to S&C for help succeeding in today’s rapidly changing business environment. Large and mid-size, public and private, throughout their lifecycles, these companies rely on our multi-disciplinary, global team to address their most complex legal and business challenges and reach their strategic goals. Sector expertise: We offer unrivaled OUR CLIENTS GET… knowledge of the healthcare and life sciences industries, our clients’ businesses and the sector-specific competitive pressures bearing down on them. Sullivan & Cromwell’s Healthcare and Life Sciences Group has negotiated complex transactions and resolved high-stakes disputes for almost three decades. Today, it possesses an unparalleled grasp of these sectors and a practical understanding of the commercial realities underlying them. We position our clients to succeed through it all. The Firm represents international clients in the following healthcare sectors: Pharmaceuticals and Life Sciences Medtech Health Insurers Healthcare Services 2 Legal expertise: Clients come to us An integrated, global team: for the high-quality counsel and hands-on We’re a core group of dedicated healthcare representation we offer across multiple advisers across our 13 offices on four legal specialties, to successfully execute continents with a strong track record of their most important deals and resolve the sector’s most significant transactions critical disputes. We can execute any type and litigation matters, supported by all of transaction in any economic climate or the resources of an integrated, global firm. geographic region. Our experience in this We’re grateful to our clients for trusting sector includes: us with their future, and we’ll continue to help them position themselves for growth M&A and success in this exciting and ever- Corporate finance changing industry.
    [Show full text]
  • Horsham Township Council
    Horsham Township PRSRT STD 1025 Horsham Road U.S. POSTAGE Horsham, PA 19044 PAID HARRISBURG, PA PERMIT NO. 609 Horsham Township Report FALL 2015 Newsletter • www.horsham.org • Published by Horsham Township Council Township Council Authorizes Review of Township Building orsham Township Council has authorized a Hrequest for proposals from architectural firms to conduct a feasibility study of the existing municipal building. The study will explore a variety of scenarios FALL 2015 Newsletter to meet the long-term facility needs. Recently, William Walker, Township Manager gave This Community Newsletter is produced for Horsham Township Council a presentation on the condition and ® hometownpress by Hometown Press • 215.257.1500 • All rights reserved This newsletter is published challenges of the existing building. The building was To Place An Ad Call Rosemary • 215-805-2121 by the Horsham Township built in three phases with the middle section built in Council to provide residents 1959, the east wing built in 1971 and the west wing with important information built in 1989. Each addition was added to meet the about their township. Township’s growing demands. Before the Police Department moved into their new building in December 2009, 64 full-time and 10 part-time TOWNSHIP MANAGER employees worked in the Township Building. With the Police relocated on the complex and William T. Walker ACE MOVING SERVICES Recreation Services now at the Library, there are 14 full-time and two part timers working in the BOARD MEETINGS building. 7.5” width x 1.75” height Township Council Due to the age of the building there are some major challenges that include a leaking roof, two 1st & 4th Monday @ 7:00PM roof mounted air conditioning units that no longer work, water infiltration into the lower level, Need artwork 2nd Wednesday @ 8:00PM deterioration of the building façade and concrete, ADA issues, security issues, old electrical fixtures Planning Commission that bulbs are no longer made for and technology that is not up to current standards.
    [Show full text]
  • The Year of Investment, Innovation and Implementation
    2017 the year of investment, innovation and implementation 2017 annual report healthcare businesswomen’s association table of contents LETTER FROM CHAIR 1 INVESTMENT 2017 BY THE NUMBERS 2 MEMBERSHIP 2 CHAPTER BREAKDOWN 2 40 YEARS OF MILESTONES 2 MEMBER/VOLUNTEER SURVEY RESULTS 3 FINANCIALS 4 INNOVATION AND IMPLEMENTATION 2017 FLAGSHIP EVENTS 7 WOMAN OF THE YEAR 8 LUMINARIES 10 RISING STARS 11 ANNUAL CONFERENCE 13 ACE AWARDS 14 THE GENDER PARITY COLLABORATIVE CLICK HERE HBA “NOW” THE NEW OPERATING MODEL CLICK HERE IN APPRECIATION—WE COULDN’T DO IT WITHOUT YOU 2017 CORPORATE PARTNERS 15 2017 SPONSORS 16 2017 MEDIA PARTNERS 17 HBA ADVISORY BOARD 18 HBA BOARD OF DIRECTORS 19 LETTER FROM CEO LAURIE COOKE 20 HBA 2017 II annual report letter from the chair In my long career as a healthcare executive, I have seen firsthand the benefits of diversity in leadership time and again. From gender to ethnicity to age and other factors, the best engagement and the most powerful results always arise when there is a diversity of perspectives in the room. This is why I joined the HBA board. This year marks the 40th anniversary of the organization’s founding. And though I am a relatively new member, I quickly became a believer in the HBA’s rich history and deep commitment to both the advancement of women individually, and to the achievement of gender parity in healthcare overall. This is also why I am proud of the HBA’s aggressive—but achievable—strategic plan to move the needle on gender parity through partnership by 2020.
    [Show full text]
  • ANNUAL and SUSTAINABILITY REPORT 2017 Forward-Looking Statements This Report Includes Forward-Looking State- Ments
    Building on our strengths Building ANNUAL AND SUSTAINABILITY REPORT 2017 Forward-looking statements This report includes forward-looking state- ments. Actual results may differ from those stated. Internal factors such as the successful management of research programmes and intellectual property rights may affect future results. There are also external conditions such as the economic climate, political changes and competing research programmes that may affect Sobi’s results. Sobi™ is an international biotechnology company dedicated to rare diseases. Our mission is to transform the lives of people with rare diseases by providing inno ­ vative therapies in our focus areas.” Guido Oelkers, CEO CONTENTS Contents This is Sobi .......................................................................4 The year in brief ..........................................................6 INTERVIEW Interview with the CEO and Chairman ......................8 CEO and Chairman Strategy .....................................................................10 8 Sobi operates throughout the entire value chain, from early research, over to clinical development and into the commercial market. Business areas ...............................................................16 “We can add significant value to our partnerships by leveraging all Haemophilia ..............................................................16 our com petencies, making us the partner of choice for a range of Specialty Care ...........................................................22 companies
    [Show full text]
  • Semi-Annual Market Review
    Semi-Annual Market Review HEALTH IT & HEALTH INFORMATION SERVICES JULY 2019 www.hgp.com TABLE OF CONTENTS 1 Health IT Executive Summary 3 2 Health IT Market Trends 6 3 HIT M&A (Including Buyout) 9 4 Health IT Capital Raises (Non-Buyout) 14 5 Healthcare Capital Markets 15 6 Macroeconomics 19 7 Health IT Headlines 21 8 About Healthcare Growth Partners 24 9 HGP Transaction Experience 25 10 Appendix A – M&A Highlights 28 11 Appendix B – Buyout Highlights 31 12 Appendix C – Investment Highlights 34 Copyright© 2019 Healthcare Growth Partners 2 HEALTH IT EXECUTIVE SUMMARY 1 An Accumulating Backlog of Disciplined Sellers Let’s chat about fireside chats. The term first used to describe a series of evening radio addresses given by U.S. President Franklin D. Roosevelt during the Great Depression and World War II is now investment banker speak for “soft launches” of sell-side and capital raise transactions. Every company has a price, and given a market of healthy valuations, more companies are testing the waters to find out whether they can achieve that price. That process now looks a little more informal, or how you might envision a fireside chat. Price (or valuation) discovery for a company can range from a single conversation with an individual buyer to a full-blown auction with hundreds of buyers and everything in between, including a fireside chat. Given the increasing share of informal conversations, the reality is that more companies are for sale than meets the eye. While the healthy valuations publicized and press-released are encouraging more and more companies to price shop, there is a simultaneous statistical phenomenon in perceived valuations that often goes unmentioned: survivorship bias.
    [Show full text]
  • Vendor Amount Paid 003851 MALPHRUS CONSTR.CO. Total
    Beaufort County Vendors Paid Fiscal Year 2007 Vendor Amount Paid 003851 MALPHRUS CONSTR.CO. Total 16,361,272.79 001166 BLUE CROSS AND BLUE Total 3,744,128.99 008161 REA CONTRACTING, LLC Total 3,172,453.95 000213 HICKORY HILL LANDFIL Total 2,936,246.25 005050 SC COUNTIES WORKERS Total 2,886,871.00 009131 UNICARE LIFE & HEALT Total 2,552,661.34 002374 BEAUFORT CONSTRUCTIO Total 1,952,819.99 004965 FIRST VEHICLE SERVIC Total 1,723,635.88 009580 PETROLEUM TRADERS Total 1,583,193.04 000391 SCE&G COMPANY Total 1,397,240.49 008956 NEWTON BUILDERS Total 1,189,505.00 005687 SCDOT Total 1,133,904.00 005133 REPUBLIC WASTE SRV O Total 1,029,027.95 004400 MOTOROLA INC Total 1,021,502.87 001546 TOWN OF BLUFFTON Total 1,000,000.00 003976 STATE BUDGET AND CO Total 925,502.05 009424 CENTURYLINK Total 855,930.15 000210 HARGRAY TELEPHONE Total 818,942.33 007283 TERRY R. LEE CONTRAC Total 699,538.00 004575 JOHNSON CONTROLS INC Total 640,746.38 002510 CAROLINA CLEANING Total 620,374.12 007859 COLUMBIA FREIGHTLINE Total 612,501.00 005570 VIC BAILEY FORD Total 597,578.00 006961 SOUTHERN HEALTH PART Total 593,926.22 000547 HOWELL GIBSON & HUGH Total 593,215.04 004936 BANK OF AMERICA Total 592,166.02 007757 BURNS AUTOMOTIVE FOR Total 542,352.54 080272 SOLICITOR'S OFFICE Total 524,607.47 000982 WILBUR SMITH & ASSOC Total 523,407.04 009807 MANATRON, INC. Total 521,365.17 009182 FLORENCE AND HUTCHES Total 507,999.46 000635 PALMETTO ELECTRIC CO Total 478,854.61 009138 STANDARD INS CO Total 466,634.61 007307 HEWLETT PACKARD Total 445,344.96 002405 SOUTHERN WASTE SERVI Total 438,023.21 009149 UNITED CONCORDIA Total 429,394.81 005122 ABL MANAGEMENT INC.
    [Show full text]
  • AMERICAN HELLENIC CHAMBER of COMMERCE Amcham.Gr
    2018-11-15_ASPROFOS_ADS_01_outline.pdf 1 15/11/2018 7:28:55 μμ C M Y CM MY CY CMY K AMERICANHELLENIC CHAMBER OF C OMMERCE amcham.gr KTX Directory AmCham fin.indd 1 9/11/2018 1:37:03 μμ .PRESS Integrated kitchen & bathroom solutions CHAMBER 60 years of expertise European manufacturing footprint Global presence in 65 countries PYRAMIS METALLOURGIA Α.Ε. 17th km Thessaloniki - Serres | P.O. Box 10 278 | 54110, Thessaloniki, Greece follow us @PyramisGroup Τel.: +30 23940 56700 | Fax.: +30 23940 71134 | [email protected] | www.pyramisgroup.com .PRESS Integrated kitchen & bathroom solutions CHAMBER 60 years of expertise European manufacturing footprint Global presence in 65 countries PYRAMIS METALLOURGIA Α.Ε. 17th km Thessaloniki - Serres | P.O. Box 10 278 | 54110, Thessaloniki, Greece follow us @PyramisGroup Τel.: +30 23940 56700 | Fax.: +30 23940 71134 | [email protected] | www.pyramisgroup.com 2018-11-15_ASPROFOS_ADS_01_outline.pdf 1 15/11/2018 7:28:55 μμ C M Y CM MY CY CMY K AMERICANHELLENIC CHAMBER OF C OMMERCE amcham.gr KTX Directory AmCham fin.indd 1 9/11/2018 1:37:03 μμ DIRECTORY 2019 AMERICANHELLENIC CHAMBER OF COMMERCE amcham.gr KTX_SPENDEO_20,8x28_Final.pdf 1 16/11/18 11:14 π.µ. 2 | DIRECTORY 2019 KTX_SPENDEO_20,8x28_Final.pdf 1 16/11/18 11:14 π.µ. contents U.S. PAGES 105 The United States Government in Greece ..... 106 The Commercial Service U.S. Embassy Athens...................... 108 U.S. Government Agencies and Offices ...... 110 Business and Professional Organizations in the United States ....................... 112 American Chambers of Commerce CHAMBER PAGES 17 in Europe ...............................
    [Show full text]
  • Guidelines with Regard to the Composition, Calculation and Management of the Index
    INDEX METHODOLOGY Solactive Pharma Breakthrough Value Index Version 2.1 dated September 03, 2020 Contents Important Information 1. Index specifications 1.1 Short Name and ISIN 1.2 Initial Value 1.3 Distribution 1.4 Prices and Calculation Frequency 1.5 Weighting 1.6 Index Committee 1.7 Publication 1.8 Historical Data 1.9 Licensing 2. Composition of the Index 2.1 Selection of the Index Components 2.2 Ordinary Adjustment 2.3 Extraordinary Adjustment 3. Calculation of the Index 3.1 Index Formula 3.2 Accuracy 3.3 Adjustments 3.4 Dividends and other Distributions 3.5 Corporate Actions 3.6 Correction Policy 3.7 Market Disruption 3.8 Consequences of an Extraordinary Event 4. Definitions 5. Appendix 5.1 Contact Details 5.2 Calculation of the Index – Change in Calculation Method 2 Important Information This document (“Index Methodology Document”) contains the underlying principles and regulations regarding the structure and the operating of the Solactive Pharma Breakthrough Value Index. Solactive AG shall make every effort to implement regulations. Solactive AG does not offer any explicit or tacit guarantee or assurance, neither pertaining to the results from the use of the Index nor the Index value at any certain point in time nor in any other respect. The Index is merely calculated and published by Solactive AG and it strives to the best of its ability to ensure the correctness of the calculation. There is no obligation for Solactive AG – irrespective of possible obligations to issuers – to advise third parties, including investors and/or financial intermediaries, of any errors in the Index.
    [Show full text]